Results 291 to 300 of about 1,067,293 (391)

Uncommon Evolution From Acute Myeloid Leukaemia to <i>JAK2</i>-Mutated Myeloproliferative Neoplasm: Evidence of Clonal Persistence and Divergence From <i>TET2</i>/<i>SRSF2</i>-Mutated Haematopoietic Progenitors. [PDF]

EJHaem
Turingan MA, Hezaveh EB, Wei C, Cheung V, Maze D, Chang H.   +5 more
europepmc   +1 more source

The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Trends in immunology, 2016
Vinit Kumar, Sima Patel, E. Tcyganov, D. Gabrilovich   +3 more
semanticscholar   +1 more source

Chronic myeloid leukemia

HemaSphere, 2019
openaire   +4 more sources

Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy

Advanced Science, EarlyView.
A vitiligo‐derived gene signature predicts response to immune checkpoint blockade across multiple cancer cohorts, providing a framework for patient stratification. Building on this, Fulvestrant—a clinically approved estrogen receptor degrader—further enhances antitumor immunity by reprogramming tumor‐associated macrophages and promoting CD8⁺ T cell ...
Jie Zhu, Liting Huang, Suzhen Bi, WeiKaixin Kong, Wanting Feng, Yingjia Li, Zhengwei Xie, Peipei Shan, Sujie Zhu   +8 more
wiley   +1 more source

The immune receptor SLAMF5 regulates myeloid-cell mediated neuroinflammation in multiple sclerosis. [PDF]

PLoS Biol
Bellassen L, David K, Lampert B, Sarusi-Portuguez A, Tsoory M, Lubliner J, Hornstein E, Osherov M, Milo R, Brenner O, Becker-Herman S, Shachar I.   +11 more
europepmc   +1 more source

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Treatment of acute myeloid leukaemia with a triple cytotoxic regime: dat

, 1977
J. K. H. Rees, R M Sandler, J Challener, F. G. J. Hayhoe   +3 more
openalex   +1 more source

Single‐Cell Transcriptomics Reveals ITGA2‐Mediated Metabolic Reprogramming and Immune Crosstalk in Pediatric Thyroid Carcinogenesis

Advanced Science, EarlyView.
This study unveils ITGA2⁺ tumor cells as key drivers of pediatric thyroid cancer aggressiveness. These cells orchestrate dual oncogenic pathways: GLUT1‐mediated glycolytic reprogramming and M2 macrophage polarization. This metabolic‐immunological crosstalk promotes tumor progression and metastasis.
Zhi‐jun Zhan, Ning Li, Yan Sun, Lu Chen, Jun‐da Yin, Yun‐han Shan, Jia‐xing Zeng, Zhe‐cheng Li, Hai‐long Tan, Neng Tang, Shi Chang, Peng Huang   +11 more
wiley   +1 more source

Haploinsufficiency for DNA methyltransferase 3A predisposes hematopoietic cells to myeloid malignancies [PDF]

, 2017
Allegra A. Petti, Amanda M. Smith, Angela M. Verdoni, Catrina Fronick, Celia V. Bangert, Christopher A. Miller, Christopher B. Cole, David A. Russler-Germain, Frith, Gue Su Chang, Jeffery M. Klco, Jeong, Mindy Guo, Nichole M. Helton, Poitras, Robert Fulton, Shamika Ketkar, Shelly O’Laughlin, Timothy J. Ley, Walter, Xi, Zheng   +21 more
core   +2 more sources

Marrow adherent cell colony-stimulating activity production in acute myeloid leukemia

, 1978
PL Greenberg, B Mara, P Heller
openalex   +1 more source